Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. PHVS
9. QQQ
10. UNFI

Go back to Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
(NASDAQ: WVE) Delayed: 4.85 -0.06 (1.22%)
Previous Close $4.91    52 Week High $38.50 
Open $4.86    52 Week Low $8.95 
Day High $4.93    P/E N/A 
Day Low $4.77    EPS $0.00 
Volume 133,632       

(NASDAQ: WVE) Delayed: 4.85 -0.06 (1.22%)
Previous Close $4.91    52 Week High $38.50 
Open $4.86    52 Week Low $8.95 
Day High $4.93    P/E N/A 
Day Low $4.77    EPS $0.00 
Volume 133,632